Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors.
暂无分享,去创建一个
Gary Larson | Shunqi Yan | J. Wu | Z. Hong | G. Larson | F. Rong | Suetying Chow | Shunqi Yan | Zhi Hong | Frank Rong | Suetying Chow | Jim Wu
[1] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[2] Gary Larson,et al. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[3] A. Alberti,et al. Management of hepatitis C. , 2003, Journal of hepatology.
[4] M. Bös,et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. , 2004, Bioorganic & medicinal chemistry letters.
[5] Uwe Koch,et al. Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site* , 2005, Journal of Biological Chemistry.
[6] M. Houghton,et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.
[7] R. Francesco,et al. Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus. , 1996, The EMBO journal.
[8] A. Siddiqui,et al. Cell-Free Replication of the Hepatitis C Virus Subgenomic Replicon , 2002, Journal of Virology.